Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy

Inclusion criteria

• Epilepsy patient over 15 years old who agrees with Informed Consent Form
• Patient who has classifiable uncontrolled partial epilepsy according to International Classification of Epileptic Seizures.
• Patient who has 3 ~ dozens of partial seizure (average more than once seizure per 4 weeks) last 12 weeks despite taking 1 ~ 3 antiepileptic drug(s).
• Patient who takes 1 ~ 3 marketed antiepileptic drug(s) excluding zonisamide at point of enrollment time.
• Before study visit, patient who takes stable dose of antiepileptic drug more than 4 weeks.

Exclusion criteria

• Patient who has progressive central nervous system (CNS) disorder and/or degenerative disease of the brain.
• Patient who experiences pseudoseizures and/or who has uncountable clusters.
• Patient who has serious systemic or drug metabolism affecting disorder .
• Upward of doubled normal glutamic oxaloacetic transaminase (GOT), glutamic pyruvic transaminase (GPT), bilirubin, blood urea nitrogen (BUN), creatinine levels.
• Patient who has absolute neutrophil counts <1800/mm3 or platelets <100,000/mm3.
• Patient who has medical history of renal stones.
• Patient who is allergic to sulfonamide.
• Medical history of medicinal poisoning and/or alcoholism and/or serious psychological disorder.
• Pregnant women, lactating women, women of childbearing age who do not use a preventive method of conception.
• A terminal patient and/or a scheduled surgical patient.
• Patient who has medication history of zonisamide.
• Patient who participated other clinical trial within the last 12 weeks at point of enrollment time of this study.